Enveric Biosciences (ENVB) Total Liabilities (2010 - 2026)
Enveric Biosciences (ENVB) posted Total Liabilities of $5.5 million for Q1 2026, up 8.35% sequentially from $5.1 million in Q4 2025, and up 8.22% YoY from $5.1 million in Q1 2025.
Enveric Biosciences (ENVB) Total Liabilities (2010 - 2026) Analysis & Trends
Enveric Biosciences has reported Total Liabilities for 17 years, with the latest figure at $5.5 million in Q1 2026.
- Quarterly Total Liabilities rose 8.22% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 8.22% YoY) and the FY2025 annual result came in at $5.1 million, up 65.32% from the prior year.
- Total Liabilities advanced to $5.5 million in Q1 2026 per ENVB's latest filing, from $5.1 million in the prior quarter.
- Over five years, Total Liabilities peaked at $15.9 million in Q1 2023 and troughed at $3.1 million in Q4 2024.
- A 5-year average of $6.3 million and a median of $5.5 million in 2026 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities sank 49.6% in 2022, then soared 104.88% in 2023.
- Over 5 years, Total Liabilities stood at $4.0 million in 2022, then rose by 7.6% to $4.3 million in 2023, then dropped by 28.31% to $3.1 million in 2024, then soared by 65.32% to $5.1 million in 2025, then increased by 8.35% to $5.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $5.5 million, $5.1 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 10.03 Bn |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - | 8.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.52 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 3.55 Mn |
| Mar 31, 2025 | 5.10 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Mar 31, 2024 | 8.85 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 6.62 Mn |
| Jun 30, 2023 | 9.80 Mn |
| Mar 31, 2023 | 15.85 Mn |
| Dec 31, 2022 | 4.00 Mn |
| Sep 30, 2022 | 7.25 Mn |
| Jun 30, 2022 | 5.97 Mn |
| Mar 31, 2022 | 7.74 Mn |
| Dec 31, 2021 | 4.41 Mn |
| Sep 30, 2021 | 14.39 Mn |
| Jun 30, 2021 | 4.88 Mn |